A genomic biomarker comprising a set of 5-50 genes is provided for predicting responsiveness to an anti-cancer treatment that includes a combination of palbociclib and sunitinib. These genes are differentially expressed in tumors that respond to the combination therapy compared to those that do not. At least some of the genes in the biomarker are significantly overexpressed in non-responsive tumors relative to responsive ones. This genomic biomarker helps determine whether a subject diagnosed with a cancerous disease will benefit from the combination therapy prior to its administration, enabling the optimization of medical treatment and supporting precision medicine.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61P 35/04 - Antineoplastic agents specific for metastasis
A method for detecting inflammation in a body joint of a subject, including: providing at least one thermal image of at least one body joint, wherein the at least one thermal image includes indications of temperature of the at least one body joint; marking at least one region of interest (ROI) in the at least one thermal image, wherein the marked ROI is a region in the at least one thermal image which includes pixels representing elevated temperatures and less elevated temperatures in the at least one thermal image; extracting values of one or more parameters of distribution of the temperature indications in the at least marked ROI; detecting inflammation in the body joint based on the extracted values.
A guide device for endotracheal intubation, comprising: (a) an elongate body, having a proximal end, a distal end, and a maximum diameter smaller than 8 mm; (b) a controllable bendable tip at the distal end of the body, bendable over a range of at least 120 degrees; and (c) at least one human-finger manipulatable control which: (i) located along said elongated body, at a distance of at least 5 mm from said proximal end, sufficient to grip the guide device at or near the control; and (ii) when manipulated, bend said tip, wherein bending said tip to 90 degrees is achieved by applying a force of no more than 3 Newton by the at least one human finger, wherein all of the device fits within a lumen of an endotracheal tube.
A61B 1/012 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor characterised by internal passages or accessories therefor
A61B 1/267 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the respiratory tract, e.g. laryngoscopes, bronchoscopes
A61B 1/05 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor combined with photographic or television appliances characterised by the image sensor, e.g. camera, being in the distal end portion
4.
METHOD AND SYSTEM FOR IDENTIFYING AN INTRABODY LOCATION BASED ON FLOW
A system for identifying a placement of an injector, within a body cavity comprising: a flow sensor, sized and shaped to be located externally to the body of the patient; and a pump, configured to generate a fluid flow through and out of the injector, wherein the flow sensor and the pump are configured to be operated in synchronization, and wherein flow properties defined by settings of the pump and settings of the flow sensor are coordinated, wherein the fluid flow can be detected by the flow sensor.
Provided is a method of fixation of an intraocular lens (IOL) comprising: (a) inserting a fixation tool posterior to the iris; (b) grasping the IOL between two flat facing surfaces of a grasper of said fixation tool; and (c) anchoring a proximal end of said grasper to a sclera. Also provided is an intraocular lens (IOL) fixation tool, comprising: (a) an elongated body comprising a trans- scleral element; (b) a grasper at a distal end of said body comprising: (i) at least two axially extending arms which define flat facing grasping surfaces, (ii) means for approximating said arms towards each other so that they grasp.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
The present invention is directed to, inter alia, a method for identifying a reference macromolecule for which a variant having improved function can be identified and/or engineered. Further provided is a macromolecule variant, such as, but not limited to Cas protein variant(s), being characterized by having improved function compared to a reference, and a method for designing same.
B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (Israel)
MOR RESEARCH APPLICATIONS LTD. (Israel)
Inventor
Gotnayer, Lotem
Vidavsky, Netta
Fraenkel, Merav
Yoel, Uri
Abstract
The present invention is directed to a method for diagnosing a thyroid cancer in a subject in need thereof, the method including determining presence, amount, or both, of at least one species of Zinc, Magnesium or both, wherein the species is in a microscopic calcification (MC) derived from a thyroid biopsy obtained from the subject, wherein: (a) the presence of the species; (b) alteration in the amount of the species compared to a healthy control; or (c) both, in the MC is indicative of the subject being afflicted with the thyroid cancer. Further provided are a method for treating a subject diagnosed with thyroid cancer, as well as preparing a sample including a thyroid biopsy for thyroid cancer diagnosis.
G01N 23/22 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material
A61B 10/02 - Instruments for taking cell samples or for biopsy
G01N 33/483 - Physical analysis of biological material
A method for treating adenoid cystic carcinoma (ACC) is provided, comprising co-administering at least inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6) and at least one multi-targeted receptor tyrosine kinase inhibitor (mtRTKI). The CDK 4/6 inhibitor may be at least one of palbociclib, abemaciclib and ribociclib and the mtRTKI may be at least one of sunitinib, sorafenib and pazopanib. A combination therapy with palbociclib and sunitinib provides a synergic effect in treatment of ACC.
Methods for treating leukemia are disclosed, comprising administering to a subject in need thereof therapeutically effective amounts of natural killer (NK)-derived exosomes. One non-limiting practical utilization of the NK-derived exosomes is induction therapy of acute myeloid leukemia (AML), to thereby immediately and effectively induce remission of the disease in newly diagnosed AML patients.
A system, apparatus and method for diagnosis of vaginal disorders, comprising a collection apparatus for collecting and sampling vaginal discharge or fluid and a sensing device for processing the sampling vaginal discharge or fluid, said sensing device comprising at least two lateral flow assays (LFAs).
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
11.
PERSONAL UNIVERSAL DENDROGRAMIC HOLOGRAPHIC SIGNATURE FROM EEG DATA ANALYSIS FOR DIAGNOSIS OF NEURO-PSYCHIATRIC DISEASES
There is provided a method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving EEG datasets from EEG electrodes monitoring a head of the subject, computing events for the EEG datasets, clustering the events into clusters, computing a p-adic representation of the clusters, extracting a p-adic topology from the p-adic representation of the clusters, computing a personal universal dendrogramic holographic signature (PUDHS) of the p-acid topology relative to a personalized threshold that separates between a relative large distance between events and a relatively small distance between events, the PUDHS denoting number of events below the personalized threshold, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the PUDHS relative to a medical threshold that separates between presence of the medical state and non-presence of the medical state.
The present disclosure relates to a system and methods for remote medical diagnosis and therapy and more particularly, for the patient driven diagnosis of vaginitis using multi sourced data.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
13.
OPHTHALMIC TRANSFIXING IMPLANTS FOR USE WITH INTRAOCULAR LENS, OPHTHALMIC IMPLANTATION TOOLS FOR IMPLANTING SAME, AND RELATED METHODS
Embodiments pertain to an ophthalmic transfixing implant for implantation in an eye with an implanted intraocular lens including a generally disc shaped lens body having an optical axis, the ophthalmic transfixing implant having a longitudinal centerline and comprising: a transfixing member having a proximal transfixing member end and a distal transfixing member end. The distal transfixing member end may include at least one tine for continuously transfixing the lens body. The proximal transfixing member end intended to have an ocular wall engaging member attached thereto for anchoring the ophthalmic transfixing implant to an eye's ocular wall thereby enabling a displaced implanted intraocular lens's optical axis to be aligned with an eye's visual axis. The distal transfixing member end may include a pair of spaced apart tines for transfixing the intraocular lens.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A system which can be used for carrying out a method for determining an efficacy of a transcranial magnetic stimulation (TMS) treatment, including:
delivering TMS to a patient using a TMS protocol in a TMS treatment session;
recording EEG signals before and after the delivering during the treatment session;
recording EEG signals after completion of the treatment session;
analyzing the recorded EEG signals to generate values of one or more EEG parameters;
determining an acute effect and an intermediate effect of the TMS protocol on a brain state of the patient based on a change in values of the one or more EEG parameters;
determining an efficacy of the TMS protocol based on the determined acute effect and the intermediate effect.
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
Methods and systems for predicting the onset and progression of neurodegenerative diseases using blood test data and machine learning models are disclosed. The method involves receiving blood test values for a target subject over a previous time period, extracting features from the blood test data, and applying a trained predictive model to compute a risk score indicating the probability of developing a neurodegenerative disease. The system includes a processor that executes code to perform the method and can be implemented as a standalone application, cloud-based service, or integrated with healthcare systems. The predictive models are trained using supervised learning on labeled data and can include statistical models or machine learning algorithms. The systems and methods enable early detection of neurodegenerative diseases, personalized risk prediction, and integration with existing healthcare infrastructure. By leveraging blood test data and machine learning techniques, patient outcomes may be improved.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/17 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
16.
SPECIFIC AND LABEL-FREE SENSING OF BIOSENSOR SIGNALS USING BIOLOGICAL TRANSISTORS
B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (Israel)
MOR RESEARCH APPLICATIONS LTD. (Israel)
Inventor
Shalev, Gil
Garika, Vijay
Samanta, Soumadri
Erez, Offer
Babbar, Shubham
Abstract
The present disclosure provides bio-transistors for sensing target molecules. More specifically, the present disclosure provides systems and methods for determining the presence and/or quantity of target molecules, specifically, protein-based target molecules, such as NAGase, AFP, CRP and Ferritin in a biological sample, thereby providing diagnosis and monitoring of conditions associated with the target molecules.
G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
H01L 29/205 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds including two or more compounds in different semiconductor regions
17.
SPECIFIC AND LABEL-FREE SENSING OF SMALL MOLECULE TARGETS USING BIOLOGICAL TRANSISTORS
B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (Israel)
MOR RESEARCH APPLICATIONS LTD. (Israel)
Inventor
Shalev, Gil
Samueli, Rakefet
Babbar, Shubham
Erez, Offer
Abstract
The present disclosure provides bio-transistors for sensing target molecules. More specifically, the present disclosure provides systems and methods for determining the presence and/or quantity of target molecules, specifically, small molecule targets, such as organophosphates or alternatively, naturally produces molecules such as estriol, in a biological sample, thereby providing diagnosis and monitoring of conditions associated with the target molecules.
G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
H01L 29/205 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds including two or more compounds in different semiconductor regions
A61B 5/1473 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means invasive, e.g. introduced into the body by a catheter
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human transthyretin (TTR). The anti-TTR antibodies or antigen-binding fragments thereof are useful, for example, in detecting TTR and in treating TTR amyloidosis in a subject.
A.Y.Y.T. - TECHNOLOGICAL APPLICATIONS AND DATA UPDATE LTD (Israel)
Mor Research Applications Ltd. (Israel)
Inventor
Balberg, Michal
Rubin, Jonathan
Aharon, Avihai
Ragones, Heftsi
Avni, Yael
Umansky, Daniil
Shoffel Havakuk, Hagit
Assi, Saja
Abstract
Disclosed herein is a multi-modal sensor system, including a wearable device configured to receive signals relating to a swallowing process of a subject, the wearable device including one or more surface Electromyograph sensors configured to receive signals relating to electrical potential in muscles of the throat, one or more bio-impedance sensors, one or more memories, one or more processors configured to operate one or more sensors of the wearable device, synchronize the signals to one or more predetermined events to generate a synchronization feature, receive the signals as a first diagnostic data set, analyze the first diagnostic data set, assess, based on the analysis, the swallowing process of the subject to yield an assessment output, and present the assessment output and determine a bio-impedance signal.
Embodiments pertain to a computer program comprising program instructions for the execution of a method comprising the following steps, when the computer program is run on a computer: receiving image data descriptive of tissue internal to a mammalian; providing an image analysis engine with the received image data; and determining for the received image data, by the image analysis engine, whether imaged tissue includes a tissue anomaly or not. The steps may further comprise determining, for a detected anomaly, a type of anomaly. In some examples, the determining whether imaged tissue includes a tissue anomaly or not comprises determining a probability that imaged tissue comprises an anomaly.
G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
21.
DEVICE FOR RETRIEVAL OF FOREIGN OBJECTS FROM BODILY CAVITIES
The present disclosure provides a device for foreign object extraction from a cavity of a subject. The device comprises (a) an insertion portion configured for being inserted into the cavity; (b) a reservoir configured to contain a fluidic activable adhesive substance, and for delivering the activable adhesive substance to a facing surface of the foreign object; (c) an adhesive substance actuator configured to controllably activate the adhesive substance so as to transition the adhesive substance from a non-adhesive state to an adhesive state that generates bonding to the foreign object.
A61B 17/50 - Instruments for removing foreign bodies from the human body
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
22.
A DELIVERY SHEATH FOR A VASCULAR CLOSURE DEVICE AND/OR A VASCULAR CLOSURE DEVICE
A delivery sheath used for deploying a closure device in a blood vessel includes a cylindrical wall that surrounds a passageway. The delivery sheath further includes a side window formed through the peripheral wall at a location in between its proximal and distal ends for allowing deployment of a closure device into the blood vessel through the delivery sheath.
The use of mevalonolactone is provided for treating, preventing or alleviating diseases, disorders or conditions associated, directly or indirectly, with reduced mevalonic acid production in the mevalonate pathway, for example, due to damaged or hindered HMG CoA-reductase enzyme. Oral administration of mevalonolactone is provided for treating muscle cell and/or tissue damage caused at least in part due to impaired mevalonic acid production, as effected in diseases and disorders such as myopathy, statin-associated muscle symptom (SAMS), immune-mediated necrotizing myopathy (IMNM), rhabdomyolysis, muscular toxicity syndrome, myalgia, sarcopenia, and limb girdle muscular dystrophy (LGMD).
Methods and systems for predicting the onset and progression of neurodegenerative diseases using blood test data and machine learning models are disclosed. The method involves receiving blood test values for a target subject over a previous time period, extracting features from the blood test data, and applying a trained predictive model to compute a risk score indicating the probability of developing a neurodegenerative disease. The system includes a processor that executes code to perform the method and can be implemented as a standalone application, cloud-based service, or integrated with healthcare systems. The predictive models are trained using supervised learning on labeled data, and can include statistical models or.machine learning algorithms. The systems and methods enable early detection of neurodegenerative diseases, personalized risk prediction, and integration with existing healthcare infrastructure. By leveraging blood test data and machine learning techniques, patient outcomes may be improved.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
25.
METHOD AND SYSTEM FOR PREDICTING LIVER ASSOCIATED DISEASE
A system for predicting probability for developing a liver associated disease, comprises a data processor which obtains parameters extracted from a body liquid test applied to a healthy subject, and feeds a machine learning procedure with the parameters. The machine learning procedure is trained for predicting probabilities for liver associated disease, and the processor receives from procedure an output indicative of a probability that the subject is expected to develop a liver associated disease.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
26.
DEVICES AND METHODS FOR DIAGNOSISING THYROID MEDICAL CONDITIONS
B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (Israel)
MOR RESEARCH APPLICATIONS LTD. (Israel)
Inventor
Marks, Robert
Yoel, Uri
Axelrod, Tim
Angel, Sagi
Kushmaro, Ariel
Abstract
Disclosed is a device including at least 4 sections with a unique layout which includes a surface functionalized with an agent having specific binding affinity to a target molecule, and which allows flow. Disclosed are also a kit and a method for determining and quantifying the presence of a biomarker of a thyroid medical condition in a sample.
A digital health management system is presented configured as a computerized system comprising data processing circuitry, and being configured to communicate with a patients' medical data provider and with patient's personal communication devices via a communication network. The processing circuitry comprises a digital assistant utility which comprises an interactive chat utility configured to utilize data about diagnostic screening plan, based on medical data of a specific patient in relation to specific diagnostic prescription for the patient, and to communicate with the specific patient to assist the patient to follow the diagnostic screening plan. The interactive chat utility comprises a motivational chatbot configured to utilize the medical data of the specific patient in conjunction with psychological tool(s), defining motivational interview protocol(s), and manage an interactive motivational chat with the patient. The management of the interactive motivational chat comprises interviewing the patient and dynamically determining behavioral characteristics of the patient and evaluating patient's proactivity measures of the patient with respect to the diagnostic screening plan, to thereby modify the behavioral characteristics and optimize diagnostic screening attendance and medical compliance of the patient with respect to the diagnostic screening plan.
G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
H04L 51/02 - User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail using automatic reactions or user delegation, e.g. automatic replies or chatbot-generated messages
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
28.
MONOCLONAL ANTIBODIES TARGETING THE HUMAN CD147/EMMPRIN PROTEIN
Monoclonal antibodies that target human EMMPRIN and bind to a specific epitope are provided as well as compositions and uses in treating, diagnosing and staging diseases and disorders that involve pathologic angiogenesis, such as angiogenesis-related disorders and proliferative diseases, and in particular cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A method comprises: for each specific medical intervention and/or respective clinical outcome: accessing a respective specific priority list of a respective sub-set of subjects scheduled in a prioritized sequence for treatment and/or evaluation, creating a respective specific training dataset that includes data extracted from EMRs of the respective sub-set of subjects labelled with the specific priority list, and training a respective specific machine learning model on the respective specific training dataset for generating an outcome of a respective specific priority list of a sub-set of subjects for prioritized evaluation and/or treatment, in response to an input of data extracted from EMR of the sub-set of subjects, accessing a combined prioritization component for generating an outcome of a combined priority list of subjects for prioritized evaluation and/or treatment in response to an input of outcomes of the specific machine learning models, and providing the specific models and the combined prioritization component.
G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
Embodiments relate to a suture tensioning device for tensioning a suture that is operably engaged with a soft tissue repair site. In some examples, the suture tensioning device comprises a housing having a wide proximal receiving end, and a narrow distal end, wherein the housing is configured to snugly receive a digit; and a suture tensioning mechanism that is configured to fixedly receive one or more suture portions of corresponding suture ends of a suture extending from the tissue report site within the body extremity to outside the body extremity to terminate at the suture tensioning mechanism. The device may further include a suture coupling element for fixedly coupling the one or more suture portions with the tensioning mechanism; and an adjustment device configured for controllably adapting tension on the suture.
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
Chinese herbal formulations comprising at least one herb or a component thereof from three or more different classes of Chinese herbs selected from Blood tonifying, Blood moderators, Blood heat coolers, body heat coolers and Yang tonic are provided. These herbal formulations are useful for treating pain, Blood stagnation, inflammatory and/or hormone mediated diseases, disorders and conditions, for example, endometriosis and other inflammatory and/or hormone mediated diseases of the pelvis and lower abdomen.
Methods for treating inflammation and conferring neuroprotection in the eye are provided, comprising the systemic and/or local administration of a variant of activated protein C (APC). Certain diseases, disorders or conditions caused directly by inflammation and/or neurodegeneration or featuring development of inflammation and/or neurodegeneration as a secondary stage or a complication thereof may be treated by a disclosed method, for example, retinal and/or choroidal diseases and disorders such as retinopathy, age-related macular degeneration (AMD), neurodegenerative disorders of the retina and optic nerve injury.
BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY (Israel)
MOR RESEARCH APPLICAITONS LTD (Israel)
Inventor
Zigel, Yaniv
Dafna, Eliran
Tarasiuk, Ariel
Abstract
A method of distinguishing sleep period states that a person experiences during a sleep period, the method comprising: using a non-contact microphone to acquire a sleep sound signal representing sounds made by a person during sleep; segmenting the sleep sound signals into epochs; generating a sleep sound feature vector for each epoch; providing a first model that gives a probability that a given sleep period state experienced by the person in a given epoch exhibits a given sleep sound feature vector; providing a second model that gives a probability that a first sleep period state associated with a first epoch transitions to a second sleep period state associated with a subsequent second epoch; and processing the feature vectors using the first and second models to determine a sleep period state of the person from a plurality of possible sleep period states for each of the epochs.
G16H 50/00 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
G16H 15/00 - ICT specially adapted for medical reports, e.g. generation or transmission thereof
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
A61B 5/08 - Measuring devices for evaluating the respiratory organs
Aspects of embodiments provides devices and methods for cervical locking during cerclage to prevent miscarriage or premature delivery, the device comprising a passage to guide a suture therethrough and enable closure thereof around a distal end of a cervix in a female subject, the device adapted to remain engaged around the cervix over a period of time until the suture is cut, thereby preventing miscarriage or premature delivery.
The present disclosure discloses a device for in situ endoscopic vacuum-assisted fistula- therapy having a distal portion locatable within the fistula and interconnectable proximal portion. The device of the present disclosure comprising at least one expandable unit being configured and operable to be inserted and advanced into a fistula, comprising (i) and inflatable balloon; (ii) an inner core located within the inflatable balloon; (iii) an outer expandable envelope at least partially surrounding said inflatable balloon; and (iv) at least one vacuum tube being disposed in between an outer surface of the inflatable balloon and the outer expandable envelope. The outer envelope is at least partially made of a porous material configured to allow passage of fluids from the fistula towards said at least one vacuum tube. Furthermore, said at least one vacuum tube is configured and operable to be connectable to a vacuum source to drain fluids having passed through the outer expandable envelope by applying a negative pressure.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
A61B 17/00 - Surgical instruments, devices or methods
Embodiments pertain to a non-wearable monitoring system for monitoring activity of a human in a scene including a floor. The system may comprise a plurality of remote ranging emitters which are configured to emit ranging energy towards the scene. At least one first and at least one second emitter of the plurality of emitters are arranged to cover different height sections of the scene. The plurality of remote ranging emitters is arranged to obtain, based on the emitted ranging energy, reflections. The system further comprises a plurality of sensors which are configured to receive the reflections and to convert the reflections into electronic signals to generate reflection-based data. The system is configured to determine based on the reflection-based data, a posture and/or activity of the human in the scene.
Embodiments pertain to a cranial cap, adapted for covering, at least partially or fully, a skin flap of a patient's head having undergone a craniectomy, the cranial cap comprising: a cap body; a flexible sheet adaptable to adhere to the head; wherein the cap body and the flexible sheet are sealed to form a fluid-tight cavity; a tubing connector port for removably bringing a pump in fluid communication with the cavity such to enable controlling fluid pressure in the cavity; and at least one sensor adapted and disposed to sense at least one characteristic relating to a skin flap shape for responsively providing an output descriptive of or relating to the skin flap shape; and patient posture and/or patient movement.
Methods for treatment of cornea epithelium pathologies and conditions, which may benefit from treatment of mitochondrial dysfunction, mitochondrial destruction and/or mitochondrial depletion in the eye, are disclosed. These methods comprise the transplantation of viable exogenous, isolated mitochondria to the cornea, for example, by topical application of designated eyedrops.
There is provided a computer implemented method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving a plurality of EEG datasets, each respective EEG dataset from a respective EEG electrode of a plurality of EEG electrodes monitoring a head of the subject, clustering the plurality of EEG datasets into a plurality of clusters, computing a p-adic representation of the plurality of clusters, extracting a quantum potential value from p-adic representation of the plurality of clusters, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the quantum potential relative to a threshold that separates between presence of the medical state and non-presence of the medical state.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
40.
ANTIBODIES FOR THE TREATMENT OF SYNUCLEINOPATHIES AND NEUROINFLAMMATION
Anti-alpha-synuclein antibodies and antigen-binding fragments thereof (e.g., scFvs) are provided. Also provided are methods of using the same in therapy
Embodiments pertain to an ophthalmic tool for ab-interno removal of ophthalmic tissue from a human eye, the human eye including trabecular meshwork tissue and a Schlemm's canal. The tool comprises an excise device having a longitudinal centerline, and shaped and dimensioned pull-string for snug insertion into the Schlemm's canal, and has a leading nose, and a trailing knife support with a pair of spaced apart longitudinally directed knife blades mounted upright on the knife support.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61F 9/013 - Methods or devices for eye surgery for compensation of ocular refraction
42.
IMPROVED MACROMOLECULES AND METHODS FOR DESIGNING SAME
The present invention is directed to, inter alia, a method for identifying a reference macromolecule for which a variant having improved function can be identified and/or engineered. Further provided is a macromolecule variant, such as, but not limited to Cas protein variant(s), being characterized by having improved function compared to a reference, and a method for designing same.
The present invention discloses means and methods for testing analyte levels, including glucose, comprising a chip configured for both (i) to process electrical pulses obtained from a communicable analyzing strip, and (ii)to communicate the processed digital data.
B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (Israel)
MOR RESEARCH APPLICATIONS LTD (Israel)
Inventor
Gotnayer, Lotem
Vidavsky, Netta
Fraenkel, Merav
Yoel, Uri
Abstract
The present invention is directed to a method for diagnosing a thyroid cancer in a subject in need thereof, the method including determining presence, amount, or both, of at least one species of Zinc, Magnesium or both, wherein the species is in a microscopic calcification (MC) derived from a thyroid biopsy obtained from the subject, wherein: (a) the presence of the species; (b) alteration in the amount of the species compared to a healthy control; or (c) both, in the MC is indicative of the subject being afflicted with the thyroid cancer. Further provided are a method for treating a subject diagnosed with thyroid cancer, as well as preparing a sample including a thyroid biopsy for thyroid cancer diagnosis.
G01N 33/483 - Physical analysis of biological material
G01N 23/22 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material
G01N 21/73 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light thermally excited using plasma burners or torches
A61B 10/02 - Instruments for taking cell samples or for biopsy
There is provided a method of diagnosing a medical state associated with a neuro- psychiatric disorder in a subject, comprising: receiving EEG datasets from EEG electrodes monitoring a head of the subject, computing events for the EEG datasets, clustering the events into clusters, computing a p-adic representation of the clusters, extracting a p-adic topology from the p-adic representation of the clusters, computing a personal universal dendrogramic holographic signature (PUDHS) of the p-acid topology relative to a personalized threshold that separates between a relative large distance between events and a relatively small distance between events, the PUDHS denoting number of events below the personalized threshold, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the PUDHS relative to a medical threshold that separates between presence of the medical state and non-presence of the medical state.
The present disclosure relates to a system and methods for remote medical diagnosis and therapy and more particularly, for the patient driven diagnosis of vaginitis using multi sourced data.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
47.
SYSTEM AND METHOD FOR CHARACTERIZING DROOPY EYELID
Embodiments pertain to a method for characterizing a droopy upper eyelid performed on a computer having a processor, memory, and one or more code sets stored in the memory and executed in the processor. The method may comprise capturing an image of a patient's facial features comprising an eye and a droopy upper eyelid; identifying at least one geometric feature of a pupil of the eye within the image; and determining, based on the at least one geometric feature, whether the droopy upper eyelid is vision impairing or not, or whether the droopy upper eyelid is more likely vision impairing than not vision-impairing.
A.Y.Y.T - TECHNOLOGICAL APPLICATIONS AND DATA UPDATE LTD (Israel)
Inventor
Nahum, Yoav
Handelman, Amir
Abstract
Aspects of embodiments pertain to an intraoperative ophthalmic tissue monitoring system, comprising at least one sensor configured to sense a physical quantity relating to an ophthalmic tissue characteristic of an eye. The system is further configured to provide, responsive to sensing the physical quantity, a sensor output relating to the sensed physical quantity. The system additionally comprises a processor, and a memory comprising for storing software executable by the processor for enabling the following: controlling, based on the sensor output, a characteristic of ultrasound energy for performing phacoemulsification of a lens of the eye.
A system which can be used for carrying out a method for determining an efficacy of a transcranial magnetic stimulation (TMS) treatment, including: delivering TMS to a patient using a TMS protocol in a TMS treatment session; recording EEG signals before and after the delivering during the treatment session; recording EEG signals after completion of the treatment session; analyzing the recorded EEG signals to generate values of one or more EEG parameters; determining an acute effect and an intermediate effect of the TMS protocol on a brain state of the patient based on a change in values of the one or more EEG parameters; determining an efficacy of the TMS protocol based on the determined acute effect and the intermediate effect.
A method of assessing a subject including: measuring a plurality of respirations of the subject; determining one or more respiration parameter from the plurality of respirations; and determining, using the one or more respiration parameter, one or more of: a state of consciousness of the subject; and a prognosis of the subject.
B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (Israel)
MOR RESEARCH APPLICATIONS LTD. (Israel)
Inventor
Gutmark-Little, Iris
Gutmark, Ephraim
Cavari, Yuval
Katoshevski, David
Abstract
The present disclosure relates to a device for treating obstructed airways. Specifically, the present disclosure relates to a device for treating the symptoms of diseases that cause persistent airflow limitation by applying air pressure oscillations and acoustic vibrations to the airways of a patient during treatment. The device may be used in a system that allows in- home treatment under remote supervision of a physician.
Embodiments pertain to ureteral stents for treatment of partial or full ureteral occlusion by bridging one or more ureteral occlusions, where each stent includes a tubular portion, a first spout portion and a second spout portion. The stent may have one or more tapered edges by having the smallest diameter of the first and/or the second spout portion smaller than the largest diameter of the tubular portion, and/or be of an overall length allowing the ureteral stent to be completely located within a patient's ureter once deployed therein.
A.Y.Y.T. - TECHNOLOGICAL APPLICATIONS AND DATA UPDATE LTD (Israel)
Inventor
Balberg, Michal
Rubin, Jonathan
Aharon, Avihai
Ragones, Heftsi
Avni, Yael
Umansky, Daniil
Shoffel Havakuk, Hagit
Assi, Saja
Abstract
Disclosed herein is a multi-modal sensor system, including a wearable device configured to receive signals relating to a swallowing process of a subject, the wearable device including one or more surface Electromyograph sensors configured to receive signals relating to electrical potential in muscles of the throat, one or more bio-impedance sensors, one or more memories, one or more processors configured to operate one or more sensors of the wearable device, synchronize the signals to one or more predetermined events to generate a synchronization feature, receive the signals as a first diagnostic data set, analyze the first diagnostic data set, assess, based on the analysis, the swallowing process of the subject to yield an assessment output, and present the assessment output and determine a bio-impedance signal.
The present invention provides a composition based on cannabidiol (CBD) and chitosan for use in reducing blood cholesterol, blood LDL and blood triglycerides levels.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A method of predicting an analyte level comprises receiving a time-ordered series of levels of the analyte, monitored over a time-period; feeding a trained neural network procedure with the monitored levels; and displaying, based on an output received from the procedure, a predicted level of the analyte in a future time. The procedure can comprise a plurality of layers, wherein for at least one pair of layers, a number of inter-layer connections within the pair is higher for later monitored levels than for earlier monitored levels.
The use of mevalonolactone is provided for treating, preventing or alleviating diseases, disorders or conditions associated, directly or indirectly, with reduced mevalonic acid production in the mevalonate pathway, for example, due to damaged or hindered HMG CoA-reductase enzyme. Oral administration of mevalonolactone is provided for treating muscle cell and/or tissue damage caused at least in part due to impaired mevalonic acid production, as effected in diseases and disorders such as myopathy, statin-associated muscle symptom (SAMS), immune- mediated necrotizing myopathy (IMNM), rhabdomyolysis, muscular toxicity syndrome, myalgia, sarcopenia, and limb girdle muscular dystrophy (LGMD).
Aspects of embodiments pertain to a perineal protection device for reducing the risk or preventing perineal tear during birth. The device may comprise a reinforcement shield that is releasably connectable to a female perineum of a subject, the reinforcement shield having a surface geometry substantially corresponding to an underlying perineal muscle structure and being configured to reduce deformation of the perineum during childbirth. Optionally, the perineal protection device further comprises a fastener arrangement for releasably securing the reinforcement shield to the female perineum. The fastener arrangement may comprise a support pad that is adhesively engageable with the subject and/or straps for strapping the reinforcement shield to the subject.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 17/00 - Surgical instruments, devices or methods
Methods of treating damaged bile ducts by way of elevating glutathione (GSH) levels, restoring normal GSH levels, and/or maintaining normal GSH levels in the biliary ducts are disclosed. A disclosed method comprises local treatment of damaged biliary ducts, e.g., by directly delivering to the bile ducts lumen of at least one active agent that promotes increasing of GSH production or inhibiting of GSH degradation in the biliary epithelial cells.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/26 - Cyanate or isocyanate estersThiocyanate or isothiocyanate esters
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A device for stimulating one or more eye functions of individual's eye is presented. The device comprises a stimulator configured to be incorporated in or mountable on an appliance attachable to individual's face and comprising a respective at least one stimulator arrangement. The stimulator arrangement defines an interface region for covering a region of interest on the individual's face in a vicinity of the respective individual's eye, and comprises a local controller for operating the stimulator arrangement(s) to apply a stimulating effect on one or more nerves in the region of interest to affect at least one predetermined eye function. The stimulator arrangement comprises an array of individually operable stimulating elements to generate a stimulating signal at a respective location of the stimulating element within the interface region. The local controller activates a predetermined individual-specific sub-array of the stimulating elements during a stimulation session, where locations of the stimulating elements of the sub-array provide a desired spatial pattern of the stimulating effect to be applied while avoiding applications of the stimulating effect outside said locations within the interface region.
A method comprises: for each specific medical intervention and/or respective clinical outcome: accessing a respective specific priority list of a respective sub-set of subjects scheduled in a prioritized sequence for treatment and/or evaluation, creating a respective specific training dataset that includes data extracted from EMRs of the respective sub-set of subjects labelled with the specific priority list, and training a respective specific machine learning model on the respective specific training dataset for generating an outcome of a respective specific priority list of a sub-set of subjects for prioritized evaluation and/or treatment, in response to an input of data extracted from EMR of the sub-set of subjects, accessing a combined prioritization component for generating an outcome of a combined priority list of subjects for prioritized evaluation and/or treatment in response to an input of outcomes of the specific machine learning models, and providing the specific models and the combined prioritization component.
G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
61.
COMPOSITION OF CANNABIDIOL FOR USE IN THE TREATMENT AND PREVENTION OF BRONCHIOLITIS OBLITERANS
The present invention is directed to a pharmaceutical composition comprising Cannabidiol and a method of use thereof, i.e., for treating or preventing bronchiolitis obliterans in a subject.
B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (Israel)
MOR RESEARCH APPLICATIONS LTD. (Israel)
Inventor
Marks, Robert
Yoel, Uri
Axelrod, Tim
Angel, Sagi
Kushmaro, Ariel
Abstract
Disclosed is a device including at least 4 sections with a unique layout which includes a surface functionalized with an agent having specific binding affinity to a target molecule, and which allows flow. Disclosed are also a kit and a method for determining and quantifying the presence of a biomarker of a thyroid medical condition in a sample.
Methods for treatment of ocular diseases and conditions associated with mitochondrial dysfunction, mitochondrial destruction and/or mitochondrial depletion in the eye, are disclosed. These methods comprise the transplantation of viable exogenous, isolated mitochondria to ocular tissues. Mitochondrial transplantation is effective in treatment of, e.g., an ocular manifestation of a disease or disorder in a subject, an ophthalmic disease, disorder or condition associated with mitochondrial dysfunction, and/or an ocular ischemic insult in a subject.
Embodiments pertain to a non-wearable monitoring system for monitoring activity of a human in a scene including a floor. The system may comprise a plurality of remote ranging emitters which are configured to emit ranging energy towards the scene. At least one first and at least one second emitter of the plurality of emitters are arranged to cover different height sections of the scene. The plurality of remote ranging emitters is arranged to obtain, based on the emitted ranging energy, reflections. The system further comprises a plurality of sensors which are configured to receive the reflections and to convert the reflections into electronic signals to generate reflection-based data. The system is configured to determine based on the reflection-based data, a posture and/or activity of the human in the scene.
Novel powerful methods for identifying, monitoring, and treating conditions associated with omics-discoverable features in human subjects, and particularly conditions such as malignant tumors are provided.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). The anti-TREM2 antibodies or antigen-binding fragments thereof are useful, for example, in detecting TREM2 and in treating neurodegenerative diseases.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
67.
DEVICES AND METHODS FOR CAPSULE SHIELDING IN CATARACT SURGERY
Aspects of embodiments pertain to a lens capsule shielding device for cataract surgery, the shielding device comprising a handle and at least one shielding element slidably mounted inside the handle. The shielding element is selectively configurable in an deployed configuration and a retracted configuration, wherein the at least one shielding element, in the deployed configuration, is operable to be positionable between lens portions of the patient's eye and posterior lens capsule portion of the eye and configured to function as a shield for preventing damage of the posterior lens capsule portion during the application of energy for fragmenting lens portions and/or for preventing damage from suction forces applied for the removal of lens fragments.
There is provided a computer implemented method of diagnosing a medical state associated with a neuro-psychiatric disorder in a subject, comprising: receiving a plurality of EEG datasets, each respective EEG dataset from a respective EEG electrode of a plurality of EEG electrodes monitoring a head of the subject, clustering the plurality of EEG datasets into a plurality of clusters, computing a p-adic representation of the plurality of clusters, extracting a quantum potential value from p-adic representation of the plurality of clusters, and diagnosing the medical state associated with the neuro-psychiatric disorder according to the quantum potential relative to a threshold that separates between presence of the medical state and non- presence of the medical state.
The present invention is directed to a system for reducing cardiac valve regurgitation, wherein said system is adapted for endovascular delivery, and comprises: a) an anchoring net of a size and shape such that it may be placed over the annulus of the cardiac valve being treated, wherein said net is perforated by a series of apertures; and b) one or more occluding plugs, each of which is of a size and shape such that it may be inserted into one of the apertures in the anchoring net, and become retained therewithin, thereby sealing said aperture. The invention also encompasses a method for reducing cardiac valve regurgitation using this system.
A61F 2/86 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure
A61F 2/90 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
70.
External eye-contact device having opaque and decentered light-transmissive portions
Embodiments concern an optical eye-contact device comprising a lens body having a symmetry axis and which further comprises a light-transmissive portion and an opaque portion, wherein the light-transmissive portion is decentered with respect to the symmetry axis.
G02C 7/16 - Shades, shieldsObturators, e.g. with pinhole, with slot
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
The present invention provides methods of treating solid cancer by co-administering an inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6) and multi-targeted receptor tyrosine kinase inhibitor (mt RTKI). Particular examples of CDK 4/6 inhibitor are palbociclib, abemaciclib and ribociclib and of mt RTKI are sunitinib, sorafenib and pazopanib. Administration of the combination may confer a synergic effect in treatment solid tumors. In particular synergic combinations of palbociclib with sunitinib or sorafenib are provided that synergically inhibit progression of a plurality of solid cancer types. The invention also provides pharmaceutical compositions comprising combinations of CDK 4/6 inhibitors and mt RTKIs and their use in treating solid cancer.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Embodiments pertain to a method for characterizing a droopy upper eyelid performed on a computer having a processor, memory, and one or more code sets stored in the memory and executed in the processor. The method may comprise capturing an image of a patient's facial features comprising an eye and a droopy upper eyelid; identifying at least one geometric feature of a pupil of the eye within the image; and determining, based on the at least one geometric feature, whether the droopy upper eyelid is vision impairing or not, or whether the droopy upper eyelid is more likely vision impairing than not vision-impairing.
A.Y.Y.T. - TECHNOLOGICAL APPLICATIONS AND DATA UPDATE LTD (Israel)
Inventor
Nahum, Yoav
Handelman, Amir
Abstract
Aspects of embodiments pertain to an intraoperative ophthalmic tissue monitoring system, comprising at least one sensor configured to sense a physical quantity relating to an ophthalmic tissue characteristic of an eye. The system is further configured to provide, responsive to sensing the physical quantity, a sensor output relating to the sensed physical quantity. The system additionally comprises a processor, and a memory comprising for storing software executable by the processor for enabling the following: controlling, based on the sensor output, a characteristic of ultrasound energy for performing phacoemulsification of a lens of the eye.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
A61B 17/00 - Surgical instruments, devices or methods
75.
Device, system and method for monitoring a surgical site
Embodiments relate to an implantable device for detecting leakage of matter from a mammalian lumen, the device comprising a mesh structure that is attachable to a lumen of a mammalian. The mesh structure comprises a material or a material composition that is electrically conductive and which is measurably responsive in terms of its electrical conductivity when being subjected to leakage of matter from the lumen.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/053 - Measuring electrical impedance or conductance of a portion of the body
A61B 5/0538 - Measuring electrical impedance or conductance of a portion of the body invasively, e.g. using a catheter
A61B 17/11 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for performing anastomosisButtons for anastomosis
A61B 5/145 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value
A61B 17/00 - Surgical instruments, devices or methods
Methods for alleviating vitreous hemorrhage in a subject afflicted with non-spontaneously clearing vitreous hemorrhage are provided, comprising administering to the subject a therapeutically effective amount of one or more red blood cell (RBC)-epitope binding agents which may be, for example, an anti-RBC antibody, a non-specific antibody and/or an antigen binding fragment thereof. Particular methods for alleviating vitreous hemorrhage comprise the use of a mixture of blood group-specific anti-RBC antibodies as the RBC-epitope binding agents.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A method of assessing a subject including: measuring a plurality of respirations of the subject; determining one or more respiration parameter from the plurality of respirations; and determining, using the one or more respiration parameter, one or more of: a state of consciousness of the subject; and a prognosis of the subject.
Ureteral stents 100 for treatment of partial or full ureteral occlusion by bridging one or more ureteral occlusions, where each stent includes a tubular portion 110, a first spout portion 120 and a second spout portion 130. The stent may have one or more tapered edges by having the smallest diameter of the first and/or the second spout portion smaller than the largest diameter of the tubular portion, and/ or be of an overall length allowing the ureteral stent to be completely located within a patient's ureter once deployed therein.
A method of predicting an analyte level comprises receiving a time-ordered series of levels of the analyte, monitored over a time-period; feeding a trained neural network procedure with the monitored levels; and displaying, based on an output received from the procedure, a predicted level of the analyte in a future time. The procedure can comprise a plurality of layers, wherein for at least one pair of layers, a number of inter-layer connections within the pair is higher for later monitored levels than for earlier monitored levels.
The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human transthyretin (TTR). The anti-TTR antibodies or antigen-binding fragments thereof are useful, for example, in detecting TTR and in treating TTR amyloidosis in a subject.
Systems, subsystems, devices and methods for oral cavity inspection may be based on acquisition of images of different oral cavity areas of a subject, and may comprise using at least one image acquisition device; determining a relative field of view (FOV) of the at least one image acquisition device, for each of the acquired images; and construction of display data, based on the acquired images, for visually representing one or more oral cavity areas of the respective subject. The constructed display data of the respective subject may be used for remote oral cavity inspection of the respective subject.
G06T 7/70 - Determining position or orientation of objects or cameras
A61B 1/247 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor for the mouth, i.e. stomatoscopes, e.g. with tongue depressorsInstruments for opening or keeping open the mouth with means for viewing areas outside the direct line of sight, e.g. dentists' mirrors
A61C 1/08 - Machine parts specially adapted for dentistry
Aspects of embodiments pertain to a fetus positioning device, comprising: a plurality of expandable members that are coupleable with each other; wherein the plurality of selectively expandable members are configured such that when coupled with each other and operably engaged with a pregnant female subject, the plurality of expandable members are arranged relative to female subject allowing to selectively apply, through expansion, forces onto the abdomen of the female subject.
Aspects of embodiments pertain to a perineal protection device for reducing the risk or preventing perineal tear during birth. The device may comprise a reinforcement shield that is releasably connectable to a female perineum of a subject, the reinforcement shield having a surface geometry substantially corresponding to an underlying perineal muscle structure and being configured to reduce deformation of the perineum during childbirth. Optionally, the perineal protection device further comprises a fastener arrangement for releasably securing the reinforcement shield to the female perineum. The fastener arrangement may comprise a support pad that is adhesively engageable with the subject and/or straps for strapping the reinforcement shield to the subject.
Methods of treating damaged bile ducts by way of elevating glutathione (GSH) levels, restoring normal GSH levels, and/or maintaining normal GSH levels in the biliary ducts are disclosed. A disclosed method comprises local treatment of damaged biliary ducts, e.g., by directly delivering to the bile ducts lumen of at least one active agent that promotes increasing of GSH production or inhibiting of GSH degradation in the biliary epithelial cells.
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/59 - Compounds containing 9,10-seco-cyclopenta[a]hydro- phenanthrene ring systems
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/26 - Cyanate or isocyanate estersThiocyanate or isothiocyanate esters
85.
Antibodies for the treatment of synucleinopathies and neuroinflammation
Anti-alpha-synuclein antibodies and antigen-binding fragments thereof (e.g., scFvs) are provided. Also provided are methods of using the same in therapy.
Methods for treating and/or preventing choroidal neovascularization (CNV) or retinal leakage associated with CNV are disclosed, comprising the use of activated protein C (APC) and/or an APC variant. A disclosed method may be applied in the treatment or prevention of ocular diseases, disorders or conditions that are caused directly by CVN, feature development of CNV as a secondary stage or a complication thereof, and/or feature CNV as a synchronous or asynchronous sequela thereof. An exemplary disease treatable by a disclosed method is neovascular age-related macular degeneration (nAMD).
Peptides, peptidomimetics and small molecules, collectively referred to as “decoy peptides”, are provided, which interfere with binding to a TIR domain of a toll-like receptor 4 (TLR4), and inhibit a TLR4-induced signaling pathway. These decoy peptides may be useful for treating diseases associated with induction of TLR4 signaling pathway such as a disease or disorder secondary to a cardiovascular disease, sepsis or an inflammatory disease.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07D 239/47 - One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
C07K 5/083 - Tripeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07K 5/087 - Tripeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
C07K 5/103 - Tetrapeptides the side chain of the first amino acid being acyclic, e.g. Gly, Ala
C07K 5/107 - Tetrapeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
C07K 5/113 - Tetrapeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
88.
Methods for identifying and monitoring pregnant women at risk of preeclampsia
Methods and kits for identifying an increased risk of developing preeclampsia in a pregnant woman based on expression pattern of non-coding RNAs in body fluids are provided. In particular, the methods provide information for identifying a pregnant woman as being at risk of developing preeclampsia by analyzing the pattern of non-coding RNAs in body fluids during early stages of pregnancy.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
The present invention is directed to a pharmaceutical composition comprising Cannabidiol and a method of use thereof, i.e., for treating or preventing bronchiolitis obliterans in a subject.
B.G. Negev Technologies and Applications Ltd., at Ben Gurion University (Israel)
Mor Research Applications Ltd. (Israel)
Inventor
Gutmark-Little, Iris
Gutmark, Ephraim
Cavari, Yuval
Katoshevski, David
Abstract
A device for unblocking and removing secretions from airways, including small airways, by applying oscillated air flow and acoustic vibrations, illustratively according to preprogrammed protocol that defines at least one of frequency, waveform, pressure amplitude, and oscillation duration. In an illustrative embodiment, the device applies a combination of air flow oscillations and acoustic waves to facilitate detachment of mucus from airway walls by matching the resonance of specific airway sections and mucus, amplifying the effect. For optimization, an algorithm illustratively matches the required frequencies, amplitudes, duty cycle, and/or relative phases to specific patient and secretion characteristics.
Methods for treatment of ocular diseases and conditions associated with mitochondrial dysfunction, mitochondrial destruction and/or mitochondrial depletion in the eye, are disclosed. These methods comprise the transplantation of viable exogenous, isolated mitochondria to ocular tissues. Mitochondrial transplantation is effective in treatment of, e.g., an ocular manifestation of a disease or disorder in a subject, an ophthalmic disease, disorder or condition associated with mitochondrial dysfunction, and/or an ocular ischemic insult in a subject.
Aspects of embodiments pertain to a lens capsule shielding device for cataract surgery, the shielding device comprising a handle and at least one shielding element slidably mounted inside the handle. The shielding element is selectively configurable in an deployed configuration and a retracted configuration, wherein the at least one shielding element, in the deployed configuration, is operable to be positionable between lens portions of the patient's eye and posterior lens capsule portion of the eye and configured to function as a shield for preventing damage of the posterior lens capsule portion during the application of energy for fragmenting lens portions and/or for preventing damage from suction forces applied for the removal of lens fragments.
The present invention provides a composition based on cannabidiol (CBD) and chitosan for use in reducing blood cholesterol, blood LDL and blood triglycerides levels.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
94.
EARLY DETECTION OF MULTIPLE RESISTANCES TO ANTI-BACTERIAL TREATMENT
Method and kits for non-invasive diagnosis of possible multiple mutated DNA-based resistances of H. pylori to distinct anti-H. pylori treatment modalities are provided. The methods and kits are based on the use of molecular multiplex means for profiling H. pylori DNA extracted form stool. Diagnosis methods disclosed herein enable the design of personalized treatment regimens that would be effective in eradicating H. pylori of any genetic profile.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
Using microstate data to evaluate Alzheimer's disease including dementia and/or mild cognitive impairment and/or depression and optionally provide treatment based on the diagnosis and/or modify treatment and/or diagnosis based on response to treatment, optionally as measured using microstate data. In one example, the method includes analyzing EEG data to generate one or more EEG parameter; and generating a risk for one or both of depression and MCI (mild cognitive impairment) based on said one or more EEG parameters. Optionally, the disease comprises MCI. Optionally, the disease comprises depression. Optionally, the one or more EEG parameter comprises a microstate-derived parameter. Optionally, the one or more EEG parameter comprises a microstate duration derived parameter.
The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research (Israel)
Mor Research Applications Ltd. (Israel)
Inventor
Koltai, Hinanit
Kapulnik, Yoram
Mazuz, Moran
Naftali, Timna
Abstract
A method of treating an inflammatory disease in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a liquid chromatography fraction of a cannabis extract comprising at least 75% tetrahydrocannabinolic acid (THCA), wherein the fraction comprises cannabis derived active ingredients other than the THCA.
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
The present invention provides methods of treating solid cancer by co-administering an inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6) and multi-targeted receptor tyrosine kinase inhibitor (mt RTKI). Particular examples of CDK 4/6 inhibitor are palbociclib, abemaciclib and ribociclib and of mt RTKI are sunitinib, sorafenib and pazopanib. Administration of the combination may confer a synergic effect in treatment solid tumors. In particular synergic combinations of palbociclib with sunitinib or sorafenib are provided that synergically inhibit progression of a plurality of solid cancer types. The invention also provides pharmaceutical compositions comprising combinations of CDK 4/6 inhibitors and mt RTKIs and their use in treating solid cancer.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (Israel)
MOR RESEARCH APPLICATIONS LTD. (Israel)
Inventor
Dafna, Eliran
Zigel, Yaniv
Ben Or, Dvir
Halevi, Matan
Tarasiuk, Ariel
Abstract
The present invention relates to a system and method for determining sleep quality parameters according to audio analyses, comprising: obtaining an audio recorded signal comprising sleep sounds of a subject; segmenting the signal into epochs; generating a feature vector for each epoch, wherein each of said feature vectors comprises one or more feature parameters that are associated with a particular characteristic of the signal and that are calculated according to the epoch signal or according to a signal generated from the epoch signal; inputting the generated feature vectors into a machine learning classifier and applying a preformed classifying model on the feature vectors that outputs a probabilities vector for each epoch, wherein each of the probabilities vectors comprises the probabilities of the epoch being each of the sleep quality parameters; inputting the probabilities vectors for each epoch into a machine learning time series model and applying a preformed sleep quality time series pattern function on said probabilities vectors that outputs an enhanced probabilities vector for each epoch; determining a final sleep quality parameter for each epoch by calculating the most probable sleep quality parameters sequence.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
